Item 1.01. Entry into a Material Definitive Agreement.

On January 17, 2023, Aadi Bioscience, Inc. (the "Company") entered into Amendment No.1 (the "Amendment") to the Negotiated Purchase Order Terms and Conditions for Clinical and Commercial Product (the "Agreement") with Fresenius Kabi, LLC ("Fresenius Kabi"). Pursuant to the Amendment, among other things, the term of the Agreement was extended until March 31, 2024 (or such later date as may be agreed upon between the parties), and certain terms related to pricing and the Company's obligation to purchase certain minimum quantities of Fyarro from Fresenius Kabi were updated and revised.

The Amendment contains other customary terms applicable to the manufacture of therapeutics in the biotechnology industry. The foregoing summary is not complete and is qualified in its entirety by reference to the Amendment, which will be filed as an exhibit in a subsequent periodic report of the Company to be filed under the Securities Exchange Act of 1934, as amended.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses